Physician profile
Charles Ho
NPI 1801902051
$2,535.25
in general payments reported to CMS, 2019-2025
23 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $460 · 2021: $749 · 2022: $387 · 2023: $166 · 2024: $323 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $326.29 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $305.47 | 2019-2023 | |
| Abbott Laboratories | $250.84 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $192.22 | 2020-2024 | Repatha, Otezla |
| Lilly USA, LLC | $161.96 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.58 | 2019-2021 | |
| Nalu Medical, INC. | $146.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $143.90 | 2019-2021 | |
| Curonix LLC | $105.86 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Astrazeneca Pharmaceuticals LP | $104.43 | 2022-2024 | Airsupra |
| Amarin Pharma, INC. | $91.81 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $86.59 | 2019-2020 | |
| Abbvie INC. | $83.50 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $73.66 | 2019-2020 | |
| Almatica Pharma LLC | $60.28 | 2021-2024 | Loreev Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51.76 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $44.63 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $43.22 | 2022 | |
| Eisai INC. | $35.67 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $24.00 | 2021 | |
| Shield Therapeutics INC | $20.05 | 2023 | Accrufer |
| Redhill Biopharma INC. | $16.00 | 2021 | |
| Glaxosmithkline, LLC. | $14.75 | 2023 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.